118 related articles for article (PubMed ID: 33011530)
21. Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics.
Liu T; Toriyabe Y; Kazak M; Berkman CE
Biochemistry; 2008 Dec; 47(48):12658-60. PubMed ID: 18983168
[TBL] [Abstract][Full Text] [Related]
22. Preparation and evaluation of carborane-derived inhibitors of prostate specific membrane antigen (PSMA).
El-Zaria ME; Genady AR; Janzen N; Petlura CI; Beckford Vera DR; Valliant JF
Dalton Trans; 2014 Apr; 43(13):4950-61. PubMed ID: 24481236
[TBL] [Abstract][Full Text] [Related]
23. Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.
Wang X; Tsui B; Ramamurthy G; Zhang P; Meyers J; Kenney ME; Kiechle J; Ponsky L; Basilion JP
Mol Cancer Ther; 2016 Aug; 15(8):1834-44. PubMed ID: 27297866
[TBL] [Abstract][Full Text] [Related]
24. Structure-activity relationships of 2',5'-oligoadenylate analogue modifications of prostate-specific membrane antigen (PSMA) antagonists.
Wang X; Tian H; Lee Z; Heston WD
Nucleosides Nucleotides Nucleic Acids; 2012 May; 31(5):432-44. PubMed ID: 22497258
[TBL] [Abstract][Full Text] [Related]
25. Small-molecule PSMA ligands. Current state, SAR and perspectives.
Machulkin AE; Ivanenkov YA; Aladinskaya AV; Veselov MS; Aladinskiy VA; Beloglazkina EK; Koteliansky VE; Shakhbazyan AG; Sandulenko YB; Majouga AG
J Drug Target; 2016 Sep; 24(8):679-93. PubMed ID: 26887438
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
28. Novel multifunctional
Kwon YD; Lee JY; La MT; Lee SJ; Lee SH; Park JH; Kim HK
Eur J Med Chem; 2020 Mar; 189():112099. PubMed ID: 32014792
[TBL] [Abstract][Full Text] [Related]
29. Discovery of PSMA-specific peptide ligands for targeted drug delivery.
Jin W; Qin B; Chen Z; Liu H; Barve A; Cheng K
Int J Pharm; 2016 Nov; 513(1-2):138-147. PubMed ID: 27582001
[TBL] [Abstract][Full Text] [Related]
30. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
Afshar-Oromieh A; Babich JW; Kratochwil C; Giesel FL; Eisenhut M; Kopka K; Haberkorn U
J Nucl Med; 2016 Oct; 57(Suppl 3):79S-89S. PubMed ID: 27694178
[TBL] [Abstract][Full Text] [Related]
31. Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain.
Majer P; Hin B; Stoermer D; Adams J; Xu W; Duvall BR; Delahanty G; Liu Q; Stathis MJ; Wozniak KM; Slusher BS; Tsukamoto T
J Med Chem; 2006 May; 49(10):2876-85. PubMed ID: 16686531
[TBL] [Abstract][Full Text] [Related]
32. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
34. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
35. PSMA-Oriented Target Delivery of Novel Anticancer Prodrugs: Design, Synthesis, and Biological Evaluations of Oligopeptide-Camptothecin Conjugates.
Xu B; Zhou F; Yan MM; Cai DS; Guo WB; Yang YQ; Jia XH; Zhang WX; Li T; Ma T; Wang PL; Lei HM
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347770
[TBL] [Abstract][Full Text] [Related]
36. Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen.
Lupold SE; Rodriguez R
Mol Cancer Ther; 2004 May; 3(5):597-603. PubMed ID: 15141017
[TBL] [Abstract][Full Text] [Related]
37. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design.
Grams F; Reinemer P; Powers JC; Kleine T; Pieper M; Tschesche H; Huber R; Bode W
Eur J Biochem; 1995 Mar; 228(3):830-41. PubMed ID: 7737183
[TBL] [Abstract][Full Text] [Related]
38. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
39. Enzymatic radiosynthesis of a
Lowe PT; Dall'Angelo S; Fleming IN; Piras M; Zanda M; O'Hagan D
Org Biomol Chem; 2019 Feb; 17(6):1480-1486. PubMed ID: 30681115
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
